Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders

9 Months Ended

Oct. 03, 2021

Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders


The following presents the detailed calculation of EPS:
	Three Months Ended				Nine Months Ended
(MILLIONS)	October 3, 2021		September 27, 2020		October 3, 2021		September 27, 2020
EPS Numerator––Basic
Income from continuing operations attributable to Pfizer Inc.	$	8,155	$	909	$	18,563	$	5,979
Less: Preferred stock dividends––net of tax	—		—		—		—
Income from continuing operations attributable to Pfizer Inc. common shareholders	8,155		909		18,563		5,979
Income/(loss) from discontinued operations––net of tax	(9)		560		24		2,334


Net income attributable to Pfizer Inc. common shareholders	$	8,146	$	1,469	$	18,586	$	8,313
EPS Numerator––Diluted
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions	$	8,155	$	909	$	18,563	$	5,979
Income/(loss) from discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions	(9)		560		24		2,334
Net income attributable to Pfizer Inc. common shareholders and assumed conversions	$	8,146	$	1,469	$	18,586	$	8,313
EPS Denominator
Weighted-average number of common shares outstanding––Basic	5,609		5,557		5,597		5,552
Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements	116		76		91		70
Weighted-average number of common shares outstanding––Diluted	5,725		5,633		5,688		5,622
Anti-dilutive common stock equivalents(a)	—		7		3		5

(a)These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.